文献速递骨质疏松与代谢性骨病

罗莫索单抗在绝经后骨质疏松症中较地舒单抗带来更大的骨小梁评分改善

Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
PubMed 文献 · Osteoporos Int · 2023-08-19

该研究在韩国Severance医院对174例绝经后女性(罗莫索单抗组87例、地舒单抗组87例,倾向评分1:1匹配)进行分析,罗莫索单抗组腰椎骨密度和骨小梁评分(TBS)的增幅均大于地舒单抗组(15.2% vs 6.9%,p<0.001;3.7% vs 1.7%,p=0.013);在既往使用双膦酸盐或选择性雌激素受体调节剂(SERM)的患者中,罗莫索单抗组TBS改善也大于地舒单抗组(3.9% vs 0.8%,P=0.006),而初治患者两组无显著差异(3.6% vs 2.7%,P=0.472)。

要点

  • 罗莫索单抗组腰椎骨密度增幅15.2% vs 地舒单抗组6.9%(p<0.001)。
  • 罗莫索单抗组TBS增幅3.7% vs 地舒单抗组1.7%(p=0.013)。
  • 既往使用双膦酸盐或SERM者中,罗莫索单抗组TBS改善3.9% vs 地舒单抗组0.8%(P=0.006)。

核心结论

  • 罗莫索单抗可改善绝经后骨质疏松症患者的骨量和以TBS衡量的骨质量,尤其适用于既往使用抗骨吸收药物的后续方案。

研究设计与样本

  • 在韩国Severance医院接受罗莫索单抗或地舒单抗治疗的绝经后女性数据进行分析,采用倾向评分1:1匹配,共174例(罗莫索单抗组n=87,地舒单抗组n=87)。

主要发现

  • 匹配后两组年龄(64岁)、体重、身高、既往骨折(38%)、腰椎或股骨颈骨密度(T值分别为-3.4和-2.6)及既往双膦酸盐或SERM暴露(50%)无差异。
  • 罗莫索单抗组腰椎骨密度增加15.2% vs 地舒单抗组6.9%(p<0.001),TBS增加3.7% vs 1.7%(p=0.013)。
  • 在从双膦酸盐或SERM转换的患者中,罗莫索单抗组TBS改善大于地舒单抗组(3.9% vs 0.8%,P=0.006);初治患者组无显著差异(3.6% vs 2.7%,P=0.472)。
  • 罗莫索单抗组TBS良好应答者比例高于地舒单抗组(33.3% vs 18.4%,p=0.024)。
  • 罗莫索单抗治疗12个月后,经协变量调整,TBS良好应答的比值比地舒单抗高3.85倍(调整后比值比3.85,p=0.002)。

关键数值与推荐

  • 良好应答者定义为TBS改善≥5.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In this study, romosozumab demonstrated significantly greater improvement in trabecular bone score compared to denosumab therapy in postmenopausal women previously treated with antiresorptive agents. Notably, in patients previously treated with anti-resorptive agents, treatment with romosozumab resulted in similar increases in trabecular bone score compared to that of drug-naïve patients. PURPOSE: Romosozumab significantly increases bone mineral density (BMD) and rapidly reduces fracture risk. Whether romosozumab can improve the spinal trabecular bone score (TBS) as a bone quality indicator merits further investigation. METHODS: Data for postmenopausal women starting romosozumab or denosumab treatment at Severance Hospital, Korea, were analyzed. Romosozumab and denosumab groups were 1:1 matched using propensity scores, considering relevant covariates. Good responders were defined as those with TBS improvement of 5.8% or greater. RESULTS: Overall, 174 patients (romosozumab, n = 87; denosumab, n = 87) were analyzed. Matched groups did not differ in age (64 years), weight, height, previous fracture (38%), lumbar spine or femoral neck BMD (T-score, -3.4 and -2.6, respectively), or prior bisphosphonate or selective estrogen receptor modulator (SERM) exposure (50%). The romosozumab group exhibited a greater increase in lumbar spine BMD (15.2% vs. 6.9%, p < 0.001) and TBS (3.7% vs. 1.7%, p = 0.013) than the denosumab group. In patients transitioning from bisphosphonate or SERM, romosozumab users showed greater improvement in TBS compared to denosumab users (3.9% versus 0.8%, P = 0.006); the drug-naive group showed no significant difference (3.6% versus 2.7%, P = 0.472). The romosozumab group had a higher proportion of good responders than the denosumab group (33.3% vs. 18.4%, p = 0.024). Romosozumab therapy for 12 months resulted in 3.8-fold higher odds of a good response in TBS than denosumab after covariate adjustment (adjusted odds ratio 3.85, p = 0.002). CONCLUSION: Romosozumab could improve bone mass and bone quality, measured by TBS, in postmenopausal osteoporosis, particularly as a subsequent regimen in patients previously taking anti-resorptive agents.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hong N, Shin S, Lee S, et al. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int. 2023. PMID: 37596432. doi:10.1007/s00198-023-06889-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。